ACTOnco®+ Comprehensive Genomic Profiling for Solid Tumors


ACTOnco®+ Comprehensive Genomic Profiling for Solid Tumors
Molecular Diagnostic Tests

  • Info :

    ACT Genomics
    Location: Taiwan


Description :

Information

 
| Find the Right Treatment For The Right Patient:
ACTOnco® + is an NGS-based test developed to support and answer the clinical challenges faced during the management of solid tumors, including carcinomas, sarcomas, and lymphomas. The ACTOnco+® comprises 440 specially-curated genes, 13 fusion genes with more than 350 fusion transcripts. It references the Hallmarks of Cancer to facilitating treatment strategies, which include chemotherapy, targeted therapy, immunotherapy, and pharmacogenomics.
 
| Key Features:
Comprehensive pathway-based Panel: Sequencing of 440 cancer-related genes and 13 fusion genes & more than 350 fusion transcripts covering most key cancer signaling pathways for targeted therapy
 
Predicting immunotherapy response:
Incorporating mutation burden, immune-related gene information, and MSI for a more accurate immunotherapy recommendation

Pharmacogenetics information:
Responses to treatments may be affected by inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective while causing fewer side effects.

Providing Report Consultation:
Every report is complemented with a face-to-face/phone consultation with our medical team.

 

Suitable for Most Patients:
- Newly diagnosed with complex cancer type
- Recurrent and metastatic cases
- Patient searching for treatment (and trials) options
- Diagnosed with advanced cancer or late-stage cancer

 

Short Turnaround Time: Providing a testing report in 10 working days.


Related Products :

ACTHRD™ PARP Inhibitors Treatment Selection

ACTLung™ Target Genomic Profiling for Lung Cancer

ACTMonitor®+ Liquid Biopsy for Cancer Monitoring